Phase 3 Trial Testing Darolutamide in Castration-resistant Prostate Cancer Expected to Conclude in September

Phase 3 Trial Testing Darolutamide in Castration-resistant Prostate Cancer Expected to Conclude in September
A Phase 3 clinical trial evaluating darolutamide (ODM-201) as a treatment for castration-resistant prostate cancer patients at high risk for metastasis is expected to conclude in September 2018, Orion, the therapy’s maker, announced. Initiated in 2014, the ARAMIS trial (NCT02200614) is part of a collaboration between Orion and Bayer to develop the investigational androgen receptor inhibitor. This multicenter, randomized

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

  1. Stephen B. Strum says:

    After 35 years in the field of prostate cancer and hearing terms like hormone-refractory prostate cancer (HRPC), androgen-independent prostate cancer (AIPC) and castration resistant PC (CRPC), one would think that in a study involving an androgen receptor antagonist, that we would rethink the term CRPC. Clearly this is not castrate resistant, androgen-independent or hormone-refractory. How about androgen receptor dysregulated PC (ARDPC)?

Leave a Comment

Your email address will not be published. Required fields are marked *